Published on 29/11/2025

Peer Review Checklists for Ongoing Review

In the pharmaceutical industry, ensuring the integrity and quality of products is paramount. A structured and compliant approach to supplier qualification and oversight can significantly mitigate risks associated with outsourcing to Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs). This tutorial provides a step-by-step guide to creating and utilizing peer review checklists to enhance your ongoing review process, ensuring compliance with regulatory requirements such as 21 CFR Part 11 and industry standards outlined in ICH Q10.

1. Understanding Ongoing Review and Its Importance

The ongoing review process is vital in the pharmaceutical sector, particularly for organizations engaged in CMO/CDMO oversight. The objective is to continuously assess and ensure that outsourced services meet predefined quality standards. This continuous monitoring helps detect deviations early and ensures effective supplier management, thus safeguarding product quality and compliance.

In line with regulatory expectations, ongoing reviews not only encompass current performance evaluations but also serve as foundational steps towards supplier qualifications. Quality agreements are critical pieces of this puzzle, detailing the responsibilities and expectations of all parties involved. These agreements must be continuously referenced and updated during the ongoing review process to reflect any changes in regulatory standards or operational capabilities.

2. Developing a Comprehensive Quality Agreement

A quality agreement is more than just a contract; it’s a foundational document that clarifies the relationship between the pharmaceutical company and its suppliers, CMOs, or CDMOs. A well-structured quality agreement encompasses several clauses that define the responsibilities of each party, ensuring compliance with regulatory expectations.

• Scope of Work: Clearly outline the services provided, including details about manufacturing processes, technologies utilized, and quality control measures.
• Quality Expectations: Specify quality standards, including specifications for raw materials, finished products, and compliance with cGMP regulations.
• Audit Rights: Include provisions for the pharmaceutical company to conduct audits, ensuring that quality measures are being upheld and to assess compliance with the agreement.
• Change Control: Detail the process for managing changes in processes or materials that may affect the quality of the product.
• Dispute Resolution: Establish a clear path for resolving disagreements that may arise regarding the quality or performance of services rendered.

Incorporating quality agreement clauses into your ongoing review ensures that both parties are aligned on expectations and committed to maintaining product quality. Regular reviews of this document can enhance the supplier qualification process, aligning with both internal operational changes and external regulatory updates.

3. Risk Assessment Methodologies

The importance of risk in supply chain management cannot be overstated. Developing a robust risk assessment methodology is integral to the ongoing review process. ISO 31000 and other risk management frameworks provide a structured approach to identifying, analyzing, and treating risks associated with suppliers, CMOs, and CDMOs.

Engage stakeholders from various departments, including quality assurance, regulatory affairs, and manufacturing, to identify potential risks associated with each supplier or contractor. Here are some key steps:

• Identify Risks: Evaluate risks in supply chain performance that could lead to deviations from quality standards. This includes evaluating factors such as financial stability, previous audit results, and compliance history.
• Analyze Risks: Assess the potential impact and likelihood of identified risks. Use qualitative scoring to prioritize risks, and apply quantitative methods to calculate potential costs associated with failures.
• Mitigate Risks: Develop action plans to address the most significant risks, which may include enhanced monitoring, increased frequency of audits, or strategic diversification of suppliers.

Implementing these methodologies can bolster your quality assurance processes and supply chain risk assessments, satisfying regulatory body expectations concerning supply chain integrity.

4. Establishing Key Performance Indicators (KPIs)

Monitoring supplier performance through Key Performance Indicators (KPIs) is essential for evaluating ongoing compliance and effectiveness in relation to quality agreement clauses. Establishing KPIs allows for quantitative evaluation of supplier performance, moving beyond anecdotal evidence to a more structured approach to oversight.

Consider the following KPIs when assessing supplier performance:

• On-Time Delivery: Measure the percentage of materials received on time versus expected delivery dates.
• Quality Metrics: Track the rates of defects, deviations, and non-conformance reports generated from materials supplied.
• Audit Findings: Keep track of the total number of findings during vendor audits to gauge compliance levels.
• Change Notifications: Monitor the frequency and timeliness of notifications regarding changes in suppliers’ processes or products that could affect quality.

Regular review of these KPIs supports informed decision-making regarding supplier qualifications and ongoing supplier management, ultimately solidifying your relationship with CMOs and aiding in adherence to regulatory standards.

5. Performing Thorough Vendor Audits

Conducting vendor audits is a critical component of the ongoing review process. These audits ensure transparency and compliance with established quality standards outlined in both quality agreements and regulatory requirements. The process usually involves several phases: planning, execution, reporting, and follow-up.

5.1 Planning the Audit

Begin by defining the scope of the audit. This should include the specific processes, systems, and products that will be examined. It’s essential to review existing documentation, previous audit findings, and quality agreement clauses to inform your audit focus.

5.2 Executing the Audit

Execution involves onsite assessments, including interviews with key personnel, observing processes, reviewing records, and assessing the physical facilities. Compliance with cGMP regulations should be a major focus, particularly in areas concerning equipment maintenance, sanitation protocols, and training practices.

5.3 Reporting Findings and Follow-Up

Once the audit is complete, prepare a comprehensive report outlining findings, recommendations, and any areas required for improvement. It’s critical to establish timelines for corrective actions and ensure that there is a clear follow-up plan to resolve noted issues. Regular follow-ups on these actions are essential for maintaining supplier relationships and compliance.

6. Tech Transfer and Method Transfer Equivalence

The transfer of technology and methods from one environment to another is a routine occurrence in pharmaceutical manufacturing. However, ensuring that these transfers maintain equivalence in quality and effectiveness is a critical component of ongoing review practices.

To ensure method transfer equivalence, consider the following:

• Validation of Equipment: Ensure that any new equipment introduced has been validated according to established procedures and meets predefined specifications.
• Documentation Comparisons: Compare documentation specific to methods and processes being transferred, ensuring consistency and adherence to quality protocols.
• Training of Personnel: Focus on adequate training for personnel involved in new methods, emphasizing the importance of maintaining product quality and compliance with guidelines.

Establishing a structured framework for technology and method transfers will enhance ongoing review efforts and reinforce supplier qualifications as part of your quality assurance strategy.

7. Conclusion

Ensuring compliance in pharmaceutical outsourcing requires a systematic and proactive approach to supplier oversight, with a focus on ongoing reviews. By implementing structured methodologies such as peer review checklists, developing robust quality agreements, and performing thorough audits, pharmaceutical companies can significantly mitigate risks associated with third-party vendors. Adopting these practices aligns with regulatory expectations across the US, UK, and EU, facilitating a compliant and effective operational environment. Emphasizing supplier qualification and risk assessment as vital components of your ongoing review process, pharmaceutical organizations can better achieve their quality objectives and uphold the integrity of their products.